Patients with advanced melanoma responded better to PD1 blockers in phase III studies than patients with NSCLC and RCC, which were both evaluated in phase I. As a result, nivolumab has been authorized by the FDA as a first- and second-line therapy for metastatic melanoma, RCC, and squamous NSCLC. Here, PDCD1 is linked to melanoma.